most very small volumes selling mostly retail investors like you...

most very small volumes selling mostly retail investors like you and me who hasn't done extensive research look at the share holders holding more than %20 . Goldmansachs , vibrinium and rubrics . why do you think rubrics would agree for convertible notes at $6.00 . they have reps across 50 us states 46.9 million woman in the states . if only 1000 women in every state are using nextstellis $ 200*12*1000 = 24000000*50 states =100000000 only from nextstellis plus the strategic planning of adding the TXMD products then doctors would have all Mayne pharma resources and attend to their training events so by default when the talk to women about contraceptive options . they will discuss mayne pharma products . so nextstellis would sell amongst all this products . so are covering all us wide . comparing to previous years when they had all the retail generics and all the waste and inefficiencies at least now less staff , less cost and more revenue even close to Metrics . Metrics was a liability on the company . us sales alone could reach 200 m plus international you looking at half a billion turnover so yes the SP could double once they gain back investor confidence and establish themselves in the market . follow mayne pharma on linkedin and shaun . many companies are listed on the ASX and don't even have a revenue buy here at least you have that heritage to build on in Australia and the states . once EBITDA IS +VE THE SP WOULD DOUBLE LIKE LAST YEAR PLUS THE COST REDUCTION THEY WILL BE TO SHOW EBIT . LESS TO NO INTEREST AS NO DEBT EXCEPT FOR CONVERTIBLE NOTES . SO THEY DEBT FREE . Shaun did a good job cleaning up the mess Scott left